Halozyme Therapeutics (HALO) 9.04 $HALO
Baxter and Halozyme Therapeutics Get FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 12:50PM CDT
Baxter International (BAX) expects to launch HYQVIA in the U.S. in a few weeks.
FDA Approves Baxter's HYQVIA for Treatment of Adu
M2 - Mon Sep 15, 10:10AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency
M2 - Mon Sep 15, 9:55AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
KRE, XME, XES, HALO, MLNX, GMM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 11, 4:27AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR S&P Regional Banking ETF (NYSE:KRE), Xmet Inc (NYSE:XME), SPDR S&P Oil & Gas Equipment & Services ETF (NYSE:XES), Halozyme Therapeutics Inc (NASDAQ:HALO), Mellanox Technologies Ltd (NASDAQ:MLNX), SPDR S&P Emerging Markets ETF (NYSE:GMM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Why You Shouldn't Bet Against Halozyme Therapeutics (HALO) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:42AM CDT
Halozyme Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
Halozyme's PEGPH20 Program Gains Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:00PM CDT
Earlier this week, Halozyme Therapeutics' (HALO) got some good news with the FDA granting fast track designation to the PEGPH20 (PEGylated recombinant human hyaluronidase) program.
Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
PR Newswire - Wed Sep 03, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer to demonstrate an improvement in overall survival. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs.
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.
Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma
PR Newswire - Thu Aug 14, 8:30AM CDT
On Wednesday, August 13, 2014, the NASDAQ Composite ended at 4,434.13, up 1.02%, the Dow Jones Industrial Average finished the day 0.55% higher at 16,651.80, and the S&P 500 closed at 1,946.72, up 0.67%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.08, up 1.15%, with the index also advancing 4.55% in the previous three months. Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at:
Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...
Halozyme to Host second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Aug 04, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014.
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency
M2 - Mon Aug 04, 6:32AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
PR Newswire - Tue Jul 22, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
2 Small-Cap Stocks Hedge Funds Love
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jul 17, 4:15PM CDT
Credit : Dr. Partha Sarathi Sahana , Flickr. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some promising small-caps companies to your portfolio but don't have the time or...
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
New Drug Applications, Agreements, Launches, and Appointments - Analyst Notes on Curis, Enzo Biochem, AGTC, Halozyme and Magellan Health
PR Newswire - Wed Jul 02, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Curis, Inc. (NASDAQ: CRIS), Enzo Biochem, Inc. (NYSE: ENZ), Applied Genetic Technologies Corp (NASDAQ: AGTC), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Magellan Health Inc (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4361-100free.
Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme
PR Newswire - Wed Jun 25, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin® SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented EnhanzeTM (recombinant human hyaluronidase) technology to be launched in Europe.
Baxter and Halozyme Therapeutics Get FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 12:50PM CDT
Baxter International (BAX) expects to launch HYQVIA in the U.S. in a few weeks.
FDA Approves Baxter's HYQVIA for Treatment of Adu
M2 - Mon Sep 15, 10:10AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
FDA Approves Baxter's HYQVIA for Treatment of Adults with Primary Immunodeficiency
M2 - Mon Sep 15, 9:55AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter's subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].
KRE, XME, XES, HALO, MLNX, GMM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Sep 11, 4:27AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of SPDR S&P Regional Banking ETF (NYSE:KRE), Xmet Inc (NYSE:XME), SPDR S&P Oil & Gas Equipment & Services ETF (NYSE:XES), Halozyme Therapeutics Inc (NASDAQ:HALO), Mellanox Technologies Ltd (NASDAQ:MLNX), SPDR S&P Emerging Markets ETF (NYSE:GMM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
Why You Shouldn't Bet Against Halozyme Therapeutics (HALO) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Sep 08, 7:42AM CDT
Halozyme Therapeutics is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
Halozyme's PEGPH20 Program Gains Fast Track Designation - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:00PM CDT
Earlier this week, Halozyme Therapeutics' (HALO) got some good news with the FDA granting fast track designation to the PEGPH20 (PEGylated recombinant human hyaluronidase) program.
Halozyme's PEGPH20 Program In Metastatic Pancreatic Cancer Receives Fast Track Designation
PR Newswire - Wed Sep 03, 7:30AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for Halozyme's program investigating PEGPH20 (PEGylated recombinant human hyaluronidase) in combination with gemcitabine and nab-paclitaxel for the treatment of patients with metastatic pancreatic cancer to demonstrate an improvement in overall survival. The Fast Track designation process was developed by the FDA to facilitate the development, and expedite the review of drugs to treat serious or life-threatening diseases and address unmet medical needs.
Halozyme Gains on Narrower-than-Expected Loss, Revenues Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 14, 9:53AM CDT
The company's second quarter 2014 loss came in at 13 cents per share, narrower than the year-ago loss of 20 cents per share and the Zacks Consensus Estimate of a loss of 18 cents per share.
Expert Briefing on Biotech Stocks -- Nanosphere, Vanda Pharma, Synta Pharma, Halozyme Therapeutics, and Isis Pharma
PR Newswire - Thu Aug 14, 8:30AM CDT
On Wednesday, August 13, 2014, the NASDAQ Composite ended at 4,434.13, up 1.02%, the Dow Jones Industrial Average finished the day 0.55% higher at 16,651.80, and the S&P 500 closed at 1,946.72, up 0.67%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 707.08, up 1.15%, with the index also advancing 4.55% in the previous three months. Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), Synta Pharmaceuticals Corporation (NASDAQ: SNTA), Halozyme Therapeutics Inc. (NASDAQ: HALO), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS). Free research on these five companies can be accessed at:
Intercept Pharma Soars On Positive Liver Drug Data
at Investor's Business Daily - Mon Aug 11, 9:20PM CDT
Intercept Pharmaceuticals (ICPT) released new data on its experimental fatty liver drug showing the treatment is effective and has less-severe side effects than previous feared, sending shares soaring 58% to 374 in late trading on the stock market...
Halozyme to Host second Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Aug 04, 3:30PM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the second quarter 2014 on Monday, August 11, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the second quarter 2014.
FDA Advisory Committee Panel Provides Favorable Recommendation on Baxter's HyQvia for Primary Immunodeficiency
M2 - Mon Aug 04, 6:32AM CDT
DEERFIELD, Ill. and SAN DIEGO, Calif. - Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of the U.S. Food and Drug Administration (FDA) voted 15-1 that HyQvia [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], Baxter's investigational subcutaneous treatment for patients with primary immunodeficiency (PI), has a favorable risk/benefit profile.
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Jul 30, 5:00AM CDT
These under-$10 biotech stocks are within range of triggering breakout trades.
Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer
PR Newswire - Tue Jul 22, 8:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial (Study 202) evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.
2 Small-Cap Stocks Hedge Funds Love
Selena Maranjian, The Motley Fool - Motley Fool - Thu Jul 17, 4:15PM CDT
Credit : Dr. Partha Sarathi Sahana , Flickr. Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some promising small-caps companies to your portfolio but don't have the time or...
Pre-market Equity Watch on Biotech Industry -- Research on Halozyme Therapeutics, XOMA, Amicus Therapeutics, and Arena Pharma
PR Newswire - Thu Jul 10, 6:20AM CDT
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
New Drug Applications, Agreements, Launches, and Appointments - Analyst Notes on Curis, Enzo Biochem, AGTC, Halozyme and Magellan Health
PR Newswire - Wed Jul 02, 5:20AM CDT
Today, Analysts Review released its analysts' notes regarding Curis, Inc. (NASDAQ: CRIS), Enzo Biochem, Inc. (NYSE: ENZ), Applied Genetic Technologies Corp (NASDAQ: AGTC), Halozyme Therapeutics, Inc. (NASDAQ: HALO) and Magellan Health Inc (NASDAQ: MGLN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4361-100free.
Roche's Commercial Launch Of MabThera SC Triggers Milestone Payment To Halozyme
PR Newswire - Wed Jun 25, 7:00AM CDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera® SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin® SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche's oncology products using Halozyme's patented EnhanzeTM (recombinant human hyaluronidase) technology to be launched in Europe.
